Taking It For Granted - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Taking It For Granted


Pharmaceutical Technology Europe
Volume 23, Issue 10


Rich Whitworth
As editor of Pharmaceutical Technology Europe, I often have the opportunity to visit the sites of a wide variety of companies within the industry. Though differing vastly in the technologies and staff they employ, they all share one thing in common for me: the "you learn something new every day!" factor.

It is very easy to take for granted the things we use daily, especially in the (over?) developed world where we think nothing of supermarket shelves being (over?) stocked with exotic fruit, bread mountains and rivers of wine from around the globe. But in every instance, there is a company, a process and a horde of employees behind the seemingly simple task of making something "available" and maintaining that all important supply chain. And so it is with the pharma industry.

On a recent trip to a sterile manufacturing facility in Glasgow, I was once again learning something new. I had not previously considered the processes and scale of the equipment necessary to produce even the simplest of solutions (buffers!) required in the volume and, more importantly, the quality required by the biopharmaceutical industry. The water-for-injection plant was an amazing feat of engineering in itself and the house-size mixing tanks put figures like 10000 litres into real perspective.

More often than not, the simplicity of the material belies its manufacturing process and it becomes a commodity. Perhaps to such a point, that we stop questioning its origin at all. I think we all agree that quality and patient safety must be at the top of everyone's agenda, but in the face of increasingly fierce competition and a never ending quest by customers for lower costs, perhaps something, somewhere has got to give?

On a completely different topic, several people have asked me if the crossword on the front cover of our September issue "works" — it does indeed. And so as not to take for granted the sense of reader anticipation in the air, the answers are included below.

I very much look forward to meeting some of you at CPhI 2011 this month; feel free to stop by at booth number 51F53 to meet the PTE team.

Best wishes,
Rich Whitworth

Across
1. PSD 6. Generic 10. Isolator 13. TSA 14. Bioconjugate

Down 2. Synthesis 3. Crystallise 4. Precipitation 5. Microdose 7. Cytotoxic 8. Blockbuster 9. Cytostatic 11. MAB 12. HPAPI

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology Europe,
Click here